Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL6997235 | 0.98 | RAB9A (0.53) | RAB9ANPC1CA12CA9LTA4H | |
| Hydrochloric Acid SCHEMBL5760483 | 0.98 | RAB9A (0.53) | RAB9ANPC1CA12CA9LTA4H | |
| SCHEMBL17083316 | 0.89 | TAAR1 (0.58) | LTA4HALDH1A1KDM4ETSHRUSP2 | |
| SCHEMBL4741844 | 0.87 | KMT2A (0.65) | RAB9ALTA4HACHEKMT2AMEN1 | |
| SCHEMBL3106474 | 0.86 | RAB9A (0.53) | RAB9ANPC1CA12CA9ALDH1A1 | |
| SCHEMBL6444116 | 0.86 | RAB9A (0.53) | RAB9ANPC1CA12CA9ALDH1A1 | |
| SCHEMBL20340713 | 0.85 | RAB9A (0.53) | RAB9ANPC1CA12CA9ALDH1A1 | |
| SCHEMBL4182138 | 0.84 | CARM1 (0.53) | RAB9ANPC1CA12CA9ALDH1A1 | |
| SCHEMBL17083311 | 0.84 | PYCR1 (0.50) | RAB9ALTA4HALDH1A1KMT2AMEN1 | |
| SCHEMBL4182133 | 0.84 | RAB9A (0.52) | RAB9ANPC1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3945811-A | CROSSLINKED MACRORETICULAR RESIN | ROHM AND HAAS COMPANY (US) | 1976-03-23 | — | — | US | claimed |
| CN-120208797-A | Preparation method of epinephrine | 上海现代哈森（商丘）药业有限公司 | 2025-06-27 | — | — | CN | disclosed |
| CN-115584631-B | Treating agent for synthetic fibers and synthetic fibers | 竹本油脂株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-115584631-A | Treating agent for synthetic fiber and synthetic fiber | 竹本油脂株式会社 | 2023-01-10 | — | — | CN | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5386009-A | Lipopeptide derivatives | MERCK & CO. INC. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5385884-A | Water-soluble, injectible echinocandins; fungicides; antiprotozoa agents, yeasts | MERCK & CO. INC. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| US-5330973-A | Fungicides, antiprotozoa agents | MERCK & CO., INC. (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0503960-A1 | Cyclic lipopeptides having antibiotic activity | MERCK & CO. INC. (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0448354-A2 | Lipopeptide derivatives | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0448343-A2 | Lipopeptide derivatives | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| US-3945811-A | CROSSLINKED MACRORETICULAR RESIN | ROHM AND HAAS COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | RAB9A 2545/4885NPC1 72/4885CA12 3444/4885 |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | RAB9A 2129/4885NPC1 1244/4885CA12 2206/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | RAB9A 2463/4885NPC1 65/4885CA12 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.